ImmunityBio (IBRX) Change in Cash (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Change in Cash of $117.0 million for Q1 2026, up 241.41% year-over-year from $34.3 million in Q1 2025, and up 316.6% quarter-over-quarter from $28.1 million in Q4 2025.
ImmunityBio (IBRX) Change in Cash (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Change in Cash for 13 consecutive years, with $117.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 241.41% year-over-year to $117.0 million; the TTM figure through Mar 2026 stood at $145.3 million (up 301.21% YoY), while the FY2025 annual figure was -$54.5 million, up 55.3% from the prior year.
- Change in Cash advanced to $117.0 million in Q1 2026 per IBRX's latest filing, from $28.1 million in the prior quarter.
- Across five years, Change in Cash topped out at $134.5 million in Q3 2023 and bottomed at -$144.7 million in Q1 2022.
- Historically, Change in Cash has averaged $1.5 million across 5 years, with a median of $480000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Cash tumbled 1582.14% — and 2023, when it soared 18127.08%.
- ImmunityBio's Change in Cash stood at $480000.0 in 2022, then jumped by 18127.08% to $87.5 million in 2023, then slumped by 63.87% to $31.6 million in 2024, then fell by 11.13% to $28.1 million in 2025, then soared by 316.6% to $117.0 million in 2026.
- Business Quant data shows IBRX's Change in Cash at $117.0 million in Q1 2026, $28.1 million in Q4 2025, and -$76.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -129.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129.52 Mn |
| Mar 31, 2026 | 117.04 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Sep 30, 2025 | -76.81 Mn |
| Jun 30, 2025 | 77.00 Mn |
| Mar 31, 2025 | -82.77 Mn |
| Dec 31, 2024 | 31.61 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | -132.42 Mn |
| Dec 31, 2023 | 87.49 Mn |
| Sep 30, 2023 | 134.47 Mn |
| Jun 30, 2023 | -44.98 Mn |
| Mar 31, 2023 | -16.16 Mn |
| Dec 31, 2022 | 480,000.00 |
| Sep 30, 2022 | 42.26 Mn |
| Jun 30, 2022 | 25.66 Mn |
| Mar 31, 2022 | -144.72 Mn |
| Dec 31, 2021 | 116.58 Mn |
| Sep 30, 2021 | -19.43 Mn |